Victory Capital Management Inc. Trims Stock Holdings in McKesson Corporation $MCK

Victory Capital Management Inc. lowered its stake in McKesson Corporation (NYSE:MCK) by 12.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 229,534 shares of the company’s stock after selling 32,762 shares during the quarter. Victory Capital Management Inc. owned about 0.19% of McKesson worth $177,324,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of McKesson by 2.0% during the 2nd quarter. Vanguard Group Inc. now owns 12,072,090 shares of the company’s stock worth $8,846,186,000 after purchasing an additional 232,286 shares during the period. Geode Capital Management LLC lifted its stake in McKesson by 4.1% during the second quarter. Geode Capital Management LLC now owns 2,820,724 shares of the company’s stock worth $2,057,065,000 after purchasing an additional 112,224 shares in the last quarter. Alliancebernstein L.P. boosted its position in shares of McKesson by 150.4% during the second quarter. Alliancebernstein L.P. now owns 2,268,015 shares of the company’s stock worth $1,661,956,000 after buying an additional 1,362,386 shares during the period. Norges Bank acquired a new stake in shares of McKesson in the second quarter valued at $1,346,661,000. Finally, Arrowstreet Capital Limited Partnership raised its holdings in shares of McKesson by 56.4% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,236,536 shares of the company’s stock valued at $906,109,000 after buying an additional 446,060 shares during the period. 85.07% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at McKesson

In related news, EVP Thomas L. Rodgers sold 276 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $816.18, for a total value of $225,265.68. Following the completion of the sale, the executive vice president owned 2,268 shares in the company, valued at $1,851,096.24. This represents a 10.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Maria Martinez sold 349 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $939.87, for a total transaction of $328,014.63. Following the transaction, the director directly owned 301 shares in the company, valued at $282,900.87. The trade was a 53.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 1,143 shares of company stock valued at $1,046,070. Insiders own 0.08% of the company’s stock.

McKesson Price Performance

Shares of MCK opened at $995.05 on Wednesday. The firm has a fifty day moving average price of $875.61 and a 200 day moving average price of $812.05. The stock has a market cap of $121.88 billion, a PE ratio of 28.62, a price-to-earnings-growth ratio of 1.59 and a beta of 0.38. McKesson Corporation has a 1-year low of $621.88 and a 1-year high of $999.00.

McKesson (NYSE:MCK) last posted its earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. The business had revenue of $106.16 billion for the quarter, compared to analysts’ expectations of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The business’s revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, equities analysts expect that McKesson Corporation will post 32.77 EPS for the current fiscal year.

McKesson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Stockholders of record on Monday, March 2nd will be given a dividend of $0.82 per share. The ex-dividend date is Monday, March 2nd. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.3%. McKesson’s dividend payout ratio (DPR) is 9.43%.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Zacks Research downgraded McKesson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 25th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of McKesson in a report on Wednesday, December 10th. Barclays increased their target price on shares of McKesson from $960.00 to $1,050.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Weiss Ratings downgraded shares of McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a research note on Thursday, February 5th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $966.00 price objective on shares of McKesson in a research note on Thursday, January 29th. Thirteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $943.50.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.